Therapeutics

Latest Innovations

A Pro-Apoptotic Microbial Community Network Enriched in the Tissue of IPF and Lung Cancer Patients

 

 

Dr. Isaac Cann from the University of Illinois has identified biomarkers and therapeutic strategy for treatment of...

pH Activated Antimicrobial Peptides for Treatment of H pylori Infection

Dr. JJ Cheng from the University of Illinois at Urbana-Champaign has developed a helix/random confirmation switchable antimicrobial polypeptides (HRS-AMPs) that are pH...

New Drug to Reverse Alzheimer’s Disease

 

Dr. Moore has developed a new drug that could reverse the progression of Alzheimer’s disease. The drug breaks up amyloid fibrils, which are believed to be the root cause...

Novel Class of Anti-Estrogens

Drs. John and Benita Katzenellenbogen have developed a novel class of anti-estrogen compounds with the potential to act as breast cancer therapeutics. These compounds show...

Small Molecules With Antibacterial and Anticancer Activity

Dr. Hergenrother from the University of Illinois at Urbana-Champaign has developed a series of topoisomerase inhibiting small molecules...

PAC-1 combination therapy for Uveal Melanoma

Dr. Hergenrother from the University of Illinois at Urbana-Champaign has developed a new synergistic combination therapy using the small...

Ligand for Potential Treatment of Myotonic Dystrophy Type 1 (DM1)

Dr. Zimmerman from the University of Illinois at Urbana-Champaign has developed an oligomeric ligand that can have potential...

Novel Toll-Like Receptor Inhibitors for Treatment of Inflammatory Disease

Dr. Katzenellenbogen from the University of Illinois at Urbana-Champaign has developed a novel class of inhibitors capable of inhibiting Toll-like Receptor signaling....

Novel Endocannabinoid Therapeutics

Dr. Aditi Das from the University of Illinois at Urbana-Champaign has developed a novel set of therapeutic endocannabinoid derivatives....

Novel Estrogen Receptor β (ERβ) Drugs for the Treatment of Multiple Sclerosis (MS)

Currently available therapeutic agents approved for the treatment of multiple sclerosis (MS) reduce relapse rates, but do not reverse or prevent neurodegeneration nor...

Pages